GALT

At a glance

Galectin Therapeutics Inc (GALT) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Norcross, United States and has 9 employees. The company is worth $365.08M. Revenue was $0 in fiscal 2025. It reported a net loss of $30.84M. The share price is 49.2% below its 52-week high of $7.13. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $1.48M. In that quarter, 1 of them reduced the position. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$365.08M

P/E

—

Forward P/E

—

P/B

—

Dividend yield

0.00%

Payout

—

EPS

-$0.43

ROE

—

Profit margin

0.00%

Revenue growth

—

Beta

0.38

52-week high

$7.13

52-week low

$2.03

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• TS
  Two SigmaHeld

  Two Sigma Investments · Q2 2026
  $1.48M

  318.25K shares · 0.0% of portfolio
• 
  Ken GriffinHeld

  Citadel Advisors · Q2 2026
  $921.97K

  198.7K shares · 0.0% of portfolio
• RT
  Renaissance TechnologiesHeld

  Renaissance Technologies · Q2 2026
  $201.11K

  43.34K shares · 0.0% of portfolio

Indicators, year by year

The last 4 closed years, each at that year’s closing price and reported numbers.

Median of the years shown; P/E years above 200x are left out.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company